Navigation Links
Pharmacyclics Reports Results for Six and Three Months Ended December 31, 2012
Date:2/14/2013

nt with Janssen, total amounts in excess of the annual cap ("Excess Amounts") plus interest may not exceed $225 million.

The Company has recognized the Excess Amounts as a reduction to operating expenses in the current year as the Company's repayment of the Excess Amounts to Janssen is contingent and would become payable only after the third profitable calendar quarter for the product under the collaboration. Further, the Excess Amounts shall be reimbursable only from the Company's share of future full calendar quarter pre-tax profits (if any) after the third profitable calendar quarter for the product under the collaboration.

For the calendar year ended December 31, 2012, the Company's total share of collaboration expenses under the Agreement was $68.1 million. As of December 31, 2012, total Excess Amounts totaled $18.1 million, of which during the quarter ended December 31, 2012, $17.3 million was recorded as a reduction to research and development expense and $0.8 million was recorded as a reduction to general and administrative expense.

GAAP operating expenses were $40.6 million for the six months ended December 31, 2012, compared to $30.6 million for the six months ended December 31, 2011. Included in operating expenses for the six months ended December 31, 2012 is the $18.1 million reduction to operating expenses for Excess Amounts.

GAAP operating expenses were $16.7 million for the quarter ended December 31, 2012, compared to $16.0 million for the quarter ended December 31, 2011 and $23.9 million for the quarter ended September 30, 2012. Included in operating expenses for the quarter ended December 31, 2012 is the $18.1 million reduction to operating expenses for the Excess Amounts.

At December 31, 2012, the Company had cash, cash equivalents and marketable securities of $317.1 million, compared with $203.6 million at June 30, 2012. In addition, as of December 31, 2012, the Company had $26.6 million receivable from Jansse
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 54th American Society of Hematology Annual Meeting
2. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
3. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
4. Interleukin Genetics Reports Third Quarter 2011 Financial Results
5. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
6. Nile Therapeutics Reports 2011 Third Quarter Financial Results
7. Pharmasset Reports Fiscal Year End 2011 Financial Results
8. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
9. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
10. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
11. Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... MA (PRWEB) May 27, 2015 The ... is directing, via its wholly owned subsidiary, Anelixis ... potential treatment for ALS that targets the innate immune ... ALS Therapy Development Institute received from the 2014 social ... The entire sum of $4 million raised directly by ...
(Date:5/27/2015)... OAKS, Calif. , May 27, 2015  Ceres, ... has been awarded a U.S. patent for a genetic ... in areas such as research, product development and plant ... in regulating key biosynthetic processes that are the target ... offer other seed companies a commercial license to the ...
(Date:5/26/2015)... USA (PRWEB) May 26, 2015 The ... partnership with the Max Planck Society establishing ... Quantum Photonics. The center will link two of the ... and will be only the third Max Planck Centre ... the international society for optics and photonics, was ...
(Date:5/26/2015)... and HILDEN, Germany ... QIAGEN N.V. (NASDAQ: QGEN ; Frankfurt Prime ... its QIAGEN Clinical Insight ® (QCI™) bioinformatics ... to interpret and report on genomic variants identified ... applications for the bioinformatics platform are in oncology, ...
Breaking Biology Technology:Ice Bucket Challenge Advances Antibody Toward Clinical Trial for ALS 2Ice Bucket Challenge Advances Antibody Toward Clinical Trial for ALS 3Ceres Awarded Patent for Innovation in Soybean 2Ceres Awarded Patent for Innovation in Soybean 3Third Max Planck Centre in North America Inaugurated at University of Ottawa 2Third Max Planck Centre in North America Inaugurated at University of Ottawa 3QIAGEN Launches Clinical Bioinformatics Platform for Next-Generation Sequencing 2QIAGEN Launches Clinical Bioinformatics Platform for Next-Generation Sequencing 3QIAGEN Launches Clinical Bioinformatics Platform for Next-Generation Sequencing 4QIAGEN Launches Clinical Bioinformatics Platform for Next-Generation Sequencing 5
... (EST):, "CYT006-AngQb, a Vaccine Against Hypertension Targeting Angiotensin II, ... Pressure.", The American Heart Association Publishes Today an Independent News Release ... ... no, Vaccine-Related Adverse Events Reported in 12 Months Follow-Up Period., ...
... Solutions Diagnostics, ERLANGEN, Germany, Nov. 6 ... Dade Behring Holdings, Inc. The,laboratory diagnostics company ... Diagnostics. As the market leader in the ... diagnostics, Siemens now can offer its,customers a ...
... November 6 AIM-quoted drug discovery,company Verona Pharma ... the planned development of its anti-asthma and hay ... compound, RPL554, is now entering a,second 28-day experimental ... demonstrate safety, before moving onto the proof of ...
Cached Biology Technology:Presentation of Phase IIa Results for Cytos Biotechnology's Hypertension Vaccine at the American Heart Association Scientific Sessions 2007 2Presentation of Phase IIa Results for Cytos Biotechnology's Hypertension Vaccine at the American Heart Association Scientific Sessions 2007 3Presentation of Phase IIa Results for Cytos Biotechnology's Hypertension Vaccine at the American Heart Association Scientific Sessions 2007 4Presentation of Phase IIa Results for Cytos Biotechnology's Hypertension Vaccine at the American Heart Association Scientific Sessions 2007 5Presentation of Phase IIa Results for Cytos Biotechnology's Hypertension Vaccine at the American Heart Association Scientific Sessions 2007 6Presentation of Phase IIa Results for Cytos Biotechnology's Hypertension Vaccine at the American Heart Association Scientific Sessions 2007 7Siemens Completes Acquisition of Dade Behring 2Siemens Completes Acquisition of Dade Behring 3AIM-Quoted Verona Pharma Progresses Anti-Asthma Drug Studies 2
(Date:5/5/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company"), ... market, reminds investors and media that  Mr. David Tunnell ... SECURE CONNEXIONS AMERICA 2015, held in Washington DC ... conference is organized into a series of nine session tracks. ... Fraud: Where is the Trust in Cyberspace? and will ...
(Date:4/27/2015)... Apr. 27, 2015 NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, announces ... pre-order customers the first week of May, 2015 and ... of May. Gino Pereira , ... for the company as Wocket® enters the consumer market. ...
(Date:4/21/2015)... , April 21, 2015 ... evolving government policies are boosting access control systems market ... According to a recently published report by TechSci ... 2020 ", the access control systems market in ... USD1.2 billion by 2020.The access control systems market in ...
Breaking Biology News(10 mins):NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 2Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 3
... at riding a bike, tying a tie, or playing the ... explain or teach those skills to someone else. These ... whereas classroom instruction and information read in a book are ... Ashby, professor and chair of UC Santa Barbara,s Department of ...
... University] Living with HIV is difficult under the ... alcohol consumption can become particularly perilous in intricate ways ... Brown Alcohol Research Center on HIV (ARCH) funded by ... of Health, Brown University scientists will study the health ...
... the International Osteoporosis Foundation (IOF) for World Osteoporosis Day ... fractures and calls on health professionals to recognize the ... "The widespread underdiagnosis and lack of treatment of spinal ... chronic pain, deformity, disability and at high risk of ...
Cached Biology News:Frontal lobe of the brain is key to automatic responses to various stimuli, say scientists 2$7.5M grant to fund research on interaction of drinking and HIV infection 2$7.5M grant to fund research on interaction of drinking and HIV infection 3Devastating impact of spinal osteoporotic fractures revealed on World Osteoporosis Day 2
...
Alexa Fluor 647 anti-mouse Qa-2...
...
... for hunting and analyzing the rare ... EST sequencing projects, microarrays, functional screenings ... developed for normalization of cDNA enriched ... directional cloning. While most normalization methods ...
Biology Products: